1st May 2026
In the public imagination, the National Health Service is a vast, steady institution free at the point of use, resilient in crisis, and quietly dependable. But behind the scenes, a more complicated story is unfolding. Across the UK—and in devolved systems like NHS Scotland.
Rising medicine costs and intermittent drug shortages are combining to create a slow-burning but significant strain on healthcare delivery.
This is not a sudden collapse. It is something more subtle, and arguably more worrying: a system under continuous pressure, forced into constant adjustment.
💊 The shifting landscape of medicine supply
Medicine shortages in the UK today are real, but uneven. At any given time, only a relatively small percentage of drugs are in serious shortage but that statistic masks a more disruptive reality. The shortages move, affecting different medicines at different times, leaving patients and clinicians in a cycle of uncertainty.
Some categories have been particularly affected. ADHD medications, hormone replacement therapies, certain antibiotics (especially liquid forms for children), and drugs used to treat epilepsy and depression have all faced recurring supply issues. Even widely used medications like blood pressure drugs or antidepressants—have seen intermittent disruptions.
For patients, this rarely means going entirely without treatment. Instead, it means substitutions, delays, or changes in dosage or formulation. A pharmacist might offer a different brand, or a GP might switch a patient to an alternative drug altogether. These workarounds keep the system functioning but they are not cost-free. They require time, coordination, and often additional clinical oversight.
[ ]A fragile global supply chain[/b]
The root of the problem lies far beyond the local pharmacy. The UK relies heavily on global supply chains for both finished medicines and the raw ingredients used to make them. This system is efficient—but fragile.
Disruptions can come from many directions:
geopolitical tensions affecting shipping routes or raw materials
rising energy and manufacturing costs
sudden spikes in global demand
limited stock reserves due to “just-in-time” supply practices
When something goes wrong anywhere along that chain, the effects ripple quickly into the NHS.
And increasingly, those ripples are becoming waves.
The rising cost of staying well
Alongside shortages, the cost of medicines is rising sharply. Over the past several years, NHS spending on drugs has grown significantly—faster than many other parts of the health budget.
This reflects several realities:
new, often highly effective but expensive treatments entering the market
an ageing population requiring more medication
higher global production and transport costs
policy changes affecting how much the NHS pays for drugs
The result is simple in principle but complex in consequence: a larger share of NHS funding is being absorbed by medicines.
The trade-offs no one sees
The NHS does not operate with unlimited resources. When spending on one area rises, something else must adjust.
This is where the impact becomes tangible.
Higher drug costs can mean:
fewer staff hires or tighter workforce budgets
delays in expanding services
pressure on waiting times
postponement of infrastructure projects
These are not always direct or immediate effects, but they accumulate. Economists call this an “opportunity cost”—money spent on one priority cannot be spent on another.
For patients, the experience may not be framed as “medicine costs rising,” but as longer waits, fewer appointments, or stretched services.
Scotland: same pressures, different decisions
In Scotland, healthcare is managed separately through NHS Scotland, but it faces the same underlying challenges.
Drug pricing and supply are largely shaped at a UK-wide or global level, meaning Scotland cannot fully shield itself from rising costs or shortages. Instead, the difference lies in how those pressures are managed.
Scottish health boards must balance their budgets in the face of:
increasing pharmaceutical costs
workforce demands
infrastructure needs
This often leads to difficult choices—prioritising certain services, delaying others, and seeking efficiency savings wherever possible. The pressures are the same; only the levers differ.
A system that adapts but at a cost
One of the strengths of the NHS is its adaptability. Pharmacists substitute medicines. Doctors adjust treatment plans. Procurement teams negotiate prices. Policies like Serious Shortage Protocols allow flexibility when supplies run tight.
These mechanisms prevent disruption from becoming crisis.
But adaptation has limits. Each workaround adds complexity. Each substitution carries clinical implications. Each financial adjustment narrows the margin for future shocks.
The bigger picture
Taken together, medicine shortages and rising costs form part of a broader challenge:
a health system increasingly dependent on global supply chains
growing demand for treatment
finite public funding
and rising expectations from patients
The NHS is still functioning—and in many ways, performing remarkably under pressure. But the strain is real, and it is cumulative.
Pressure without collapse
There is no single moment when the system “fails.” Instead, there is a gradual tightening—a sense that everything still works, but with less room to manoeuvre.
Medicine shortages do not usually mean going without. Rising costs do not immediately translate into cuts. But together, they reshape the landscape of care in quieter ways.
A delayed prescription here.
A substituted drug there.
A postponed investment elsewhere.
Individually manageable. Collectively significant.
And at the heart of it all lies a simple truth:
In a system built on finite resources, every rising cost echoes far beyond the pharmacy shelf.